Pharmena

Pharmena Diluted EPS

The Diluted Earnings per Share of Pharmena (PHR.WA) as of Nov 1, 2026 is -0.25 PLN. In the previous year, Diluted Earnings per Share was -0.11 PLN — a change of 119.41% (lower).

Diluted EPS

-0.25PLN

YoY

119.41%

Last updated:

Diluted Earnings per Share of Pharmena is 2025 -0.25 PLN. Diluted Earnings per Share of Pharmena was 2024 -0.11 PLN. It decreases by 119.41% lower compared to the previous year.

The Pharmena Diluted EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Diluted EPS
Date
Diluted EPS
Jan 1, 2018
-0.05 PLN
Jan 1, 2019
-0.87 PLN
Jan 1, 2020
-0.62 PLN
Jan 1, 2021
-0.41 PLN
Jan 1, 2022
-0.14 PLN
Jan 1, 2023
2.60 PLN
Jan 1, 2024
-0.11 PLN
Jan 1, 2025
-0.25 PLN
The Pharmena Diluted EPS history
YEARDiluted EPSYoY
-0.25PLN+119.41%
-0.11PLN-104.36%
2.60PLN-1,943.38%
-0.14PLN-65.81%
-0.41PLN-33.36%
-0.62PLN-29.01%
-0.87PLN+1,626.29%
-0.05PLN-80.54%
-0.26PLN+43.57%
-0.18PLN-53.98%
-0.39PLN-11.50%
-0.44PLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pharmena Stock analysis

What does Pharmena do? Pharmena SA develops and markets products based on 1-MNA, a patented physiological active substance. The company sells Dermena for hair loss, Dermena Plus for dandruff and hair loss, Accos for acne, Allerco for hypo-allergic body care, Thermi for burn and sunburn relief, and Revium for anti-wrinkle treatments. Pharmena collaborates with research centers in Europe, the US, and Canada on multidirectional studies. The company has a wholly owned subsidiary, Cortria Corporation, in the US, and its main shareholder is Pelion SA, with Polska Grupa Farmaceutyczna SA holding a 43.65% stake as of 2011. Pharmena SA's revenue comes from direct sales of its product lines to consumers and healthcare providers. Dermena and Dermena Plus target individuals with hair loss concerns, while Accos and Allerco appeal to those seeking acne and sensitive skin solutions. Thermi serves patients recovering from burns, and Revium attracts customers focused on anti-aging skincare. The company’s research partnerships with European, US, and Canadian institutions support product development and market positioning. The company operates through its subsidiary Cortria Corporation in the US, expanding its market reach. Polska Grupa Farmaceutyczna SA, a significant shareholder, likely influences strategic decisions. Pharmena’s product portfolio is structured around specific health and beauty segments, with Dermena and Revium targeting cosmetic and dermatological needs, and Thermi addressing medical recovery applications. Pharmena is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pharmena stock

Diluted Earnings per Share of Pharmena is -0.25 PLN in 2025.

Diluted Earnings per Share of Pharmena changed from -0.11 PLN to -0.25 PLN, representing a 119.41% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Diluted Earnings per Share Pharmena since 2006 – with annual values, charts, and detailed analysis.

Diluted EPS accounts for all potential shares from options, warrants, and convertible securities. It provides a more conservative per-share earnings measure.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Pharmena

All Key Metrics — Pharmena